20.04.2018 • News

Wacker Buys Dutch Biotechnology Plant

Wacker Buys Dutch Biotechnology Plant (c) Wacker
Wacker Buys Dutch Biotechnology Plant (c) Wacker

With the takeover of SynCo Bio Partners of Amsterdam from SynCo Bio Luxembourg, Germany’s Wacker Chemie has acquired a Dutch manufacturing site for biopharmaceuticals, live microbial products and vaccines, along with the associated business.

Terms of the deal were not disclosed. Wacker plans to maintain SynCo’s existing customer relationships and the company’s 110 employees.

The company said the acquired facilities will enable it to satisfy robust market demand and strengthen its position as a leading contract manufacturer of microbial-derived biopharmaceutical proteins.

Founded in 2000, SynCo operates two fermentation lines with current capacities of 1,500 and 270 liters. Along with manufacturing microbial-derived biopharmaceuticals for clinical testing it also produces for the commercial market. An additional line of single-use fermenters provides additional and flexible production capabilities, Wacker said.

The Dutch company also operates a “fill and finish” facility, which enables the complete manufacture of pharmaceuticals from active agent to filled product. The plants, which meet GMP quality standards, have been inspected by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

Gerhard Schmid, president of Wacker Biosolutions, said the additional fermentation lines will double the German company’s capacity, thus enhancing its ability to produce key pharmaceuticals cost effectively, using advanced microbial techniques.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.